查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1599330

生物製造的重要蛋白質市場：按類別、功能和適應症分類 - 2025-2030 年全球預測

Vital Proteins for Biomanufacturing Market by Groups (Cytokines, Enzymes & Chemicals, Expression Systems), Function (Diagnostics, Drug Discovery & Development), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

生物製造重要蛋白質市場規模2023年為521億美元，預計2024年將達到565.2億美元，複合年成長率為8.92%，到2030年將達到948.1億美元。

生物製造中的關鍵蛋白質是治療性蛋白質、酵素和其他生化產品生產和開發的重要組成部分。其範圍包括製藥、生物技術和治療製造中的應用，促進細胞培養、蛋白質精製以及單株抗體、疫苗和重組蛋白生產所必需的配方等過程。對這些蛋白質的需求是因為它們能夠提高生物基產品的效率、產量和質量，並且它們在現代生物技術過程中發揮重要作用。最終用途產業主要包括專注於藥物開發和生命科學研究的製藥公司、研究機構和生物技術公司。該市場的推動因素包括生技藥品需求的增加、蛋白質工程的進步以及生物技術研發投資的迅速增加。永續和高效的生物程序的日益普及凸顯了商機，特別是在個人化醫療和再生療法方面。公司可以透過專注於提高生物過程效率的創新蛋白質解決方案來利用這些機會。然而，市場面臨生產成本高、監管障礙和蛋白質製造複雜性等挑戰，可能會阻礙成長。蛋白質生產的可擴展性有限和技術困難也是主要障礙。業務成長的創新領域包括開發具有成本效益的蛋白質生產技術、改進蛋白質穩定和保存方法以及在新興生物技術中為重要蛋白質創造新用途。此外，與學術和研究機構的夥伴關係促進共同創新並提供競爭優勢。該市場的特點是技術快速進步，注重永續性和效率，代表著一個具有巨大成長潛力的動態環境。公司可以透過投資研究和利用最尖端科技來滿足生物製造領域不斷變化的需求，從而保持競爭力。

主要市場統計
基準年[2023] 521億美元
預測年份 [2024] 565.2億美元
預測年份 [2030] 948.1億美元
複合年成長率（%） 8.92%

市場動態：快速發展的生物製造重要蛋白質市場的關鍵市場洞察

供需的動態交互作用正在改變生物製造的重要蛋白質市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 對具有增強治療功效的生物製藥的需求不斷增加
    • 快速採用新型細胞培養平台來生產複雜的生物製藥
    • 由於對個人化醫療的興趣日益濃厚，對客製化蛋白質療法的需求
  • 市場限制因素
    • 建立最先進的生物製造設施的高資本支出
  • 市場機會
    • 政府支持政策促進研發投入
    • 學術界和工業界持續合作以實現重要的蛋白質創新
  • 市場挑戰
    • 與擴大生產流程相關的複雜性

波特五力：駕馭生物製造重要蛋白質市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生物製造重要蛋白質市場的外部影響

外部宏觀環境因素在塑造生物製造重要蛋白質市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生物製造重要蛋白質市場的競爭狀況

對生物製造重要蛋白質市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生物製造重要蛋白質市場供應商的績效評估

FPNV 定位矩陣是評估生物製造重要蛋白質市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了生物製造重要蛋白質市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生物製造的重要蛋白質市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對具有增強治療功效的生物製藥的需求不斷增加
      • 快速部署新的細胞培養平台來生產複雜的生物製藥
      • 對個人化醫療日益成長的興趣需要客製化的蛋白質療法
    • 抑制因素
      • 建立最先進的生物製造設施需要大量資本支出
    • 機會
      • 政府支持政策促進研發投入
      • 學術界和工業界持續合作以實現重要的蛋白質創新
    • 任務
      • 與擴大生產流程相關的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生物製造市場的重要蛋白質（以群體分類）

  • 細胞激素
    • 趨化素
    • 集落刺激因子
    • 干擾素
    • 白細胞介素
    • 腫瘤壞死因子
  • 酵素和化學品
    • DNA加帽酶
    • 核酸內切酶
    • 糖苷酶
    • 聚腺苷酸化酶
    • 蛋白酶抑制劑
    • 轉錄酶
  • 表達系統
    • 細菌
    • 昆蟲
    • 哺乳動物細胞
    • 酵母菌
  • 媒體和補充品
    • 白蛋白
    • 表皮生長因子（EGF）
    • 纖維母細胞生長因子（FGF）
    • 胰島素樣生長因子 (IGF)
    • 轉鐵蛋白
    • 血管內皮生長因子（VEGF）
  • 蛋白A樹脂
  • 品管試劑
  • 載體和轉染試劑

第7章生物製造的重要蛋白質市場：依功能

  • 診斷
  • 藥物發現與開發
    • 生物製藥
    • 細胞/基因治療
    • 疫苗

第8章生物製造市場的重要蛋白質（按適應症）

  • 自體免疫疾病
  • 感染疾病
  • 腫瘤學
  • 罕見遺傳疾病

第9章美洲生物製造重要蛋白質市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太生物製造重要蛋白質市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲/中東/非洲生物製造重要蛋白質市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • New England Biolabs 推出了 Faustovirus Capping Enzyme，這是一種用於 mRNA 生產的新型酶促 mRNA 封端解決方案。
    • Everest Medicines 獲得類 3C 蛋白酶抑制劑的權利，用於開發針對 COVID-19 的抗病毒藥物
  • 戰略分析和建議

公司名單

  • Abcam PLC
  • Abnova Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioLegend, Inc. by PerkinElmer, Inc.
  • Biologics International Corporation
  • BPS Bioscience, Inc.
  • Bristol-Myers Squibb Company
  • Creative BioMart Inc.
  • Croyez Bioscience Co., Ltd.
  • Eli Lilly and Company
  • Enzo Life Sciences, Inc.
  • GenScript Biotech Corporation
  • Johnson & Johnson Services, Inc.
  • Laurus Bio Private Limited
  • LenioBio GmbH
  • Lonza Group AG
  • Merck KGaA
  • Meridian Bioscience, Inc. by SD Biosensor Inc.
  • Miltenyi Biotec BV & Co. KG
  • Novartis AG
  • ProMab Biotechnologies, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-D47730F51F28

The Vital Proteins for Biomanufacturing Market was valued at USD 52.10 billion in 2023, expected to reach USD 56.52 billion in 2024, and is projected to grow at a CAGR of 8.92%, to USD 94.81 billion by 2030.

Vital proteins in biomanufacturing serve as essential components in the production and development of therapeutic proteins, enzymes, and other biochemical products. Their scope includes applications in pharmaceuticals, biotechnology, and therapeutic manufacturing, where they facilitate processes like cell culture, protein purification, and formulation, crucial for producing monoclonal antibodies, vaccines, and recombinant proteins. The necessity of these proteins stems from their ability to enhance efficiency, yield, and quality of bio-based products, underscoring their indispensable role in modern biotechnological processes. End-use sectors primarily include pharmaceutical companies, research institutes, and biotech firms focusing on drug development and life sciences research. The market is driven by key factors such as increased demand for biologic drugs, advancements in protein engineering, and a surge in investment in biotechnological research and development. The growing adoption of sustainable and efficient bioprocesses highlights opportunities, particularly in personalized medicine and regenerative therapies. Companies can leverage these opportunities by focusing on innovative protein solutions that enhance bioprocess efficiency. However, the market faces challenges like high production costs, regulatory barriers, and the complexity of protein manufacturing, which can impede growth. Limited scalability and technical difficulties in protein production also present significant hurdles. For business growth, areas of innovation include developing cost-effective protein production technologies, improving methods of protein stabilization and storage, and creating novel applications for vital proteins in emerging biotechnologies. Additionally, partnerships with academic and research institutions can spur collaborative innovation, offering competitive advantages. The market is characterized by rapid technological advancements and a strong emphasis on sustainability and efficiency, indicating a dynamic environment with significant potential for growth. Companies can stay competitive by investing in research and harnessing cutting-edge technologies to meet the evolving demands of the biomanufacturing sector.

KEY MARKET STATISTICS
Base Year [2023] USD 52.10 billion
Estimated Year [2024] USD 56.52 billion
Forecast Year [2030] USD 94.81 billion
CAGR (%) 8.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vital Proteins for Biomanufacturing Market

The Vital Proteins for Biomanufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
    • Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
    • Growing interest in personalized medicine necessitates tailored protein therapeutics
  • Market Restraints
    • High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
  • Market Opportunities
    • Supportive government policies promoting investments in research & development
    • Ongoing collaborations between academia & industry players for technological innovations in vital proteins
  • Market Challenges
    • Complexities associated with scaling up production processes

Porter's Five Forces: A Strategic Tool for Navigating the Vital Proteins for Biomanufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vital Proteins for Biomanufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vital Proteins for Biomanufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vital Proteins for Biomanufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vital Proteins for Biomanufacturing Market

A detailed market share analysis in the Vital Proteins for Biomanufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vital Proteins for Biomanufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vital Proteins for Biomanufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vital Proteins for Biomanufacturing Market

A strategic analysis of the Vital Proteins for Biomanufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vital Proteins for Biomanufacturing Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corporation, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., GenScript Biotech Corporation, Johnson & Johnson Services, Inc., Laurus Bio Private Limited, LenioBio GmbH, Lonza Group AG, Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vital Proteins for Biomanufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Groups, market is studied across Cytokines, Enzymes & Chemicals, Expression Systems, Media & Supplements, Protein A Resins, Quality Control Reagents, and Vectors & Transfection Reagents. The Cytokines is further studied across Chemokines, Colony-stimulating factors, Interferons, Interleukins, and Tumor necrosis factors. The Enzymes & Chemicals is further studied across DNA Capping Enzymes, Endonucleases, Glycosidases, Polyadenylation Enzymes, Protease Inhibitors, and Transcription Enzymes. The Expression Systems is further studied across Bacterial, Insect, Mammalian Cells, and Yeast. The Media & Supplements is further studied across Albumin, Epidermal Growth Factor (EGF), Fibroblast Growth Factors (FGFs), Insulin-like Growth Factors (IGFs), Transferrin, and Vascular Endothelial Growth Factor (VEGF).
  • Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines.
  • Based on Indication, market is studied across Autoimmune Disorders, Infectious Diseases, Oncology, and Rare Genetic Disorders.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for biopharmaceuticals with enhanced therapeutic efficacy
      • 5.1.1.2. Rapid adoption of novel cell culture platforms to produce complex biotherapeutics
      • 5.1.1.3. Growing interest in personalized medicine necessitates tailored protein therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High capital expenditure requirements for establishing state-of-the-art biomanufacturing facilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive government policies promoting investments in research & development
      • 5.1.3.2. Ongoing collaborations between academia & industry players for technological innovations in vital proteins
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with scaling up production processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vital Proteins for Biomanufacturing Market, by Groups

  • 6.1. Introduction
  • 6.2. Cytokines
    • 6.2.1. Chemokines
    • 6.2.2. Colony-stimulating factors
    • 6.2.3. Interferons
    • 6.2.4. Interleukins
    • 6.2.5. Tumor necrosis factors
  • 6.3. Enzymes & Chemicals
    • 6.3.1. DNA Capping Enzymes
    • 6.3.2. Endonucleases
    • 6.3.3. Glycosidases
    • 6.3.4. Polyadenylation Enzymes
    • 6.3.5. Protease Inhibitors
    • 6.3.6. Transcription Enzymes
  • 6.4. Expression Systems
    • 6.4.1. Bacterial
    • 6.4.2. Insect
    • 6.4.3. Mammalian Cells
    • 6.4.4. Yeast
  • 6.5. Media & Supplements
    • 6.5.1. Albumin
    • 6.5.2. Epidermal Growth Factor (EGF)
    • 6.5.3. Fibroblast Growth Factors (FGFs)
    • 6.5.4. Insulin-like Growth Factors (IGFs)
    • 6.5.5. Transferrin
    • 6.5.6. Vascular Endothelial Growth Factor (VEGF)
  • 6.6. Protein A Resins
  • 6.7. Quality Control Reagents
  • 6.8. Vectors & Transfection Reagents

7. Vital Proteins for Biomanufacturing Market, by Function

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Drug Discovery & Development
    • 7.3.1. Biologics
    • 7.3.2. Cell & Gene Therapy
    • 7.3.3. Vaccines

8. Vital Proteins for Biomanufacturing Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Disorders
  • 8.3. Infectious Diseases
  • 8.4. Oncology
  • 8.5. Rare Genetic Disorders

9. Americas Vital Proteins for Biomanufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vital Proteins for Biomanufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vital Proteins for Biomanufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. New England Biolabs Introduces Faustovirus Capping Enzyme, a Novel Enzymatic mRNA Capping Solution for mRNA Manufacturing
    • 12.3.2. Everest Medicines Ltd. acquires rights to 3C-like protease inhibitors to develop antivirals for COVID-19
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abcam PLC
  • 2. Abnova Corporation
  • 3. Agilent Technologies, Inc.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. BioLegend, Inc. by PerkinElmer, Inc.
  • 6. Biologics International Corporation
  • 7. BPS Bioscience, Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Creative BioMart Inc.
  • 10. Croyez Bioscience Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. Enzo Life Sciences, Inc.
  • 13. GenScript Biotech Corporation
  • 14. Johnson & Johnson Services, Inc.
  • 15. Laurus Bio Private Limited
  • 16. LenioBio GmbH
  • 17. Lonza Group AG
  • 18. Merck KGaA
  • 19. Meridian Bioscience, Inc. by SD Biosensor Inc.
  • 20. Miltenyi Biotec B.V. & Co. KG
  • 21. Novartis AG
  • 22. ProMab Biotechnologies, Inc.
  • 23. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VITAL PROTEINS FOR BIOMANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VITAL PROTEINS FOR BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VITAL PROTEINS FOR BIOMANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VITAL PROTEINS FOR BIOMANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COLONY-STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TUMOR NECROSIS FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DNA CAPPING ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENDONUCLEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GLYCOSIDASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY POLYADENYLATION ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSCRIPTION ENZYMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INSECT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EPIDERMAL GROWTH FACTOR (EGF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FIBROBLAST GROWTH FACTORS (FGFS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INSULIN-LIKE GROWTH FACTORS (IGFS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY TRANSFERRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY PROTEIN A RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY QUALITY CONTROL REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VECTORS & TRANSFECTION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 202. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 219. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 220. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 222. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 227. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 228. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 229. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 230. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 235. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 236. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 237. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 238. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 239. FINLAND VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 243. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 244. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 245. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 246. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. FRANCE VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 251. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 252. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 253. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 254. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 255. GERMANY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 259. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 260. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 261. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 263. ISRAEL VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 267. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 268. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 269. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 270. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 271. ITALY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 276. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 278. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY ENZYMES & CHEMICALS, 2018-2030 (USD MILLION)
  • TABLE 283. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY EXPRESSION SYSTEMS, 2018-2030 (USD MILLION)
  • TABLE 284. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY MEDIA & SUPPLEMENTS, 2018-2030 (USD MILLION)
  • TABLE 285. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 286. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 287. NIGERIA VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY GROUPS, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY VITAL PROTEINS FOR BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, 2018-2030 (USD MILLION)
  • TABLE 290. NORW